<DOC>
	<DOC>NCT00476437</DOC>
	<brief_summary>This trial is conducted in Japan. The purpose of this trial is to investigate the safety and the effect of biphasic insulin aspart 50 compared to biphasic human insulin 50 in patients with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Type 2 diabetes mellitus Current treatment with premixed human insulin preparation or biphasic/premixed insulin analogue in twice daily treatment for at least 8 weeks. HbA1C: less than 11.0% BMI: less than 30.0 kg/m2 Total daily insulin dose: 100 IU/U and more Treatment with oral hypoglycaemic agents within the last 4 weeks. Treatment with insulin sensitizer within the last 12 weeks A lifestyle that is considered unsuitable for this trial (frequent or routine night shift workers etc.)</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>